Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
GSK and iTeos Therapeutics announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations
GSK now has the leading portfolio of antibodies targeting the CD226 axis - a key target for next-generation immuno-oncology therapies
Read more -
GSK to showcase scientific advances and progress in oncology at ASCO and EHA
GSK will showcase innovative approaches to oncology R&D and cutting-edge science at the upcoming ASCO and EHA meetings.
Read more -
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
Pending positive Phase 3 outcomes and regulatory reviews, the vaccine could be approved in Q4 2021
Read more -
GSK and Vir Biotechnology announce sotrovimab (VIR-7831) receives Emergency Use Authorization from the US FDA for treatment of mild-to-moderate COVID-19 in high-risk adults and paediatric patients
GSK and Vir Biotechnology announce sotrovimab (VIR-7831) receives Emergency Use Authorization from the US FDA
Read more -
GSK announced as a Principal Partner of COP26 UN Climate Change Conference
As Principal Partner, GSK will drive action on climate, nature and health targets in support of COP26 ambitions.
Read more -
EMA issues positive scientific opinion on GSK and Vir Biotechnology’s sotrovimab for the early treatment of COVID-19
Opinion based on the EMA’s CHMP review of available data on sotrovimab (previously VIR-7831) for the early treatment of COVID-19.
Read more -
GSK announces sale of stake in Innoviva Inc
Shares to be sold back to Innoviva at $12.25 per share
Read more -
Medicago and GSK announce positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate
Neutralizing antibody responses were ten times higher than in people recovering from COVID-19.
Read more -
Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial
Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups.
Read more -
GSK Consumer Healthcare commits to make over a billion toothpaste tubes recyclable by 2025 as part of its ongoing sustainability journey
GSKCH’s initiatives support GSK’s company wide commitment to achieve a net zero impact on climate and a positive impact on nature by 2030.
Read more -
GSK and Vir Biotechnology announce the start of the EMA rolling review of VIR-7831 (sotrovimab) for the early treatment of COVID-19
Review will support a formal Marketing Authorisation Application.
Read more -
European Commission approves Benlysta for adult patients with active lupus nephritis
First and only biologic approved for both systemic lupus erythematosus and lupus nephritis
Read more -
ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV
If approved, cabotegravir would be the first, long-acting therapy for HIV PrEP
Read more -
GSK delivers Q1 sales of £7.4 billion -18% AER, -15% CER Total EPS 21.5p, -32% AER, -25% CER; Adjusted EPS 22.9p -39% AER, -33% CER
Q1 performance reflects expected year-on-year impact and disruption from COVID-19
Read more -
European Commission approves GSK’s JEMPERLI (dostarlimab), the first anti-PD-1 therapy approved for recurrent or advanced endometrial cancer
The approval makes dostarlimab the first anti-PD-1 therapy available for endometrial cancer in Europe.
Read more -
FDA grants accelerated approval for GSK’s JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer
FDA grants accelerated approval for GSK’s JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer
Read more -
GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19
GSK and Vir continue discussions with global regulators to make VIR-7831 available to patients with COVID-19.
Read more -
GSK provides update on feladilimab, an investigational inducible T cell co-stimulatory (ICOS) agonist
GSK provides update on feladilimab, an investigational inducible T cell co-stimulatory (ICOS) agonist
Read more -
GSK announces Dr Anne Beal to join the Board as Non-Executive Director
GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that Dr Anne Beal will join the Board of the Company as a Non-Executive Director.
Read more -
GSK to support manufacture of Novavax’ COVID-19 vaccine
GSK to support manufacture of up to 60 million doses of Novavax’ COVID-19 vaccine.
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose to improve the quality of human life.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines & consumer healthcare from inside and outside our labs. Go #BehindTheScience to see for yourself
